Mounjaro vs Zepbound: What the Research Shows
Mounjaro and Zepbound side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Mounjaro if…
- you need a type 2 diabetes label: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes[5]
- you want a label that includes cardiovascular risk reduction: Mounjaro is indicated to reduce major cardiovascular events in adults with type 2 diabetes at high risk[5]
Consider Zepbound if…
- you want an FDA-approved product: Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or with overweight plus a weight-related condition[10]
- you want the label that also covers obstructive sleep apnea: Zepbound is indicated for moderate to severe obstructive sleep apnea in adults with obesity[10]
What they have in common
Spec comparison
Showing all 11 fields. Highlighted rows differ.
| Field | Mounjaro | Zepbound |
|---|---|---|
| Class | Brand of Tirzepatide (GLP-1 / GIP dual agonist) | Brand of Tirzepatide (GLP-1 / GIP dual agonist) |
| Also called | Brand name of Tirzepatide | Brand name of Tirzepatide |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | FDA approved (Mounjaro, Zepbound) | FDA approved (Mounjaro, Zepbound) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | approximately 5 dayssubcutaneous · FDA label (Mounjaro) | approximately 5 dayssubcutaneous · FDA label (Mounjaro) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 |
| Human studies we summarised | 24 human (22 randomized or controlled) of 30 summarised | 24 human (22 randomized or controlled) of 30 summarised |
| Typical study doses |
|
|
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026; 31 Mar 2026) | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Zepbound vs Mounjaro: what differs on the two labels
Mounjaro's label describes tirzepatide as a GIP receptor and GLP-1 receptor agonist indicated for type 2 diabetes in adults and in pediatric patients 10 years of age and older.[5]
Zepbound's label, by contrast, is for weight: reducing excess body weight and maintaining the reduction in adults with obesity or overweight, and treating moderate to severe obstructive sleep apnea in adults with obesity.[10]
Mounjaro's label extends to children from age 10, and its maximum dose is 10 mg weekly in pediatric patients against 15 mg in adults.[5]
For obstructive sleep apnea, Zepbound's label gives 10 mg or 15 mg injected once weekly.[10]
The Zepbound label has a diabetic retinopathy warning: patients with a history of diabetic retinopathy should be monitored for progression.[10]
Which trials sit behind each brand
A tirzepatide trial in adults with obesity and obstructive sleep apnea used the change in the apnea-hypopnea index from baseline as its primary end point.[12]
For Mounjaro, the label describes its titration in the diabetes trials: start at 2.5 mg weekly, rise by 2.5 mg every 4 weeks, up to 15 mg or the maximum tolerated dose.[5]
The Zepbound label warns that using tirzepatide with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia.[10]
Practical differences that are on the labels
The Zepbound label lists single-dose pens, single-dose vials, multi-dose vials and KwikPens. The multi-dose vials and the KwikPen each contain 4 doses.[10]
The Mounjaro label gives an elimination half-life of approximately 5 days and says this enables once-weekly dosing.[5]
The Zepbound label says weight loss offers no benefit to a pregnant patient and may cause fetal harm.[10]
The Zepbound label says patients on oral hormonal contraceptives should switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation.[10]
Common questions
Is Zepbound the same as Mounjaro?
They share the active ingredient tirzepatide and are made by the same company, but they are separate FDA products with different approved uses.[11]
Can you use Zepbound and Mounjaro together?
The Zepbound label says coadministration with other tirzepatide-containing products is not recommended, which includes using Mounjaro alongside it.[10]
Which one is approved for sleep apnea?
Zepbound. Its label lists treatment of moderate to severe obstructive sleep apnea in adults with obesity; Mounjaro's does not.[10]
Can teenagers use Mounjaro?
Mounjaro's label covers type 2 diabetes in patients 10 years of age and older, with a lower maximum dose than in adults.[5]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 7Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 8Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 9PubMed search: (Mounjaro[tiab]) AND (Zepbound[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 11Drugs@FDA (openFDA) search: active ingredient "tirzepatide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 12Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.The New England journal of medicine · 2024PMID 38912654Accessed 2 Oct 2026
Found an error? Report a correction.